Highbridge Capital Management’s Charles River Laboratories CRL Stock Holding History

Highbridge Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-123,713	Closed	-$9.43M	–	1467
2016 Q4	$9.43M	Buy	+123,713	New	+$9.4M	0.17%	162
2016 Q2	–	Sell	-64,119	Closed	-$4.87M	–	1448
2016 Q1	$4.87M	Buy	+64,119	New	+$4.75M	0.08%	283
2015 Q4	–	Sell	-168,854	Closed	-$10.7M	–	1538
2015 Q3	$10.7M	Buy	168,854 +27,298	+19%	+$1.96M	0.17%	171
2015 Q2	$9.96M	Buy	+141,556	New	+$10.5M	0.13%	185
2013 Q4	–	Sell	-14,256	Closed	-$660K	–	1100
2013 Q3	$660K	Buy	+14,256	New	+$654K	0.01%	792

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Highbridge Capital Management's CRL Position: Q1 2017 in Review

Highbridge Capital Management sold out of Charles River Laboratories (CRL) in Q1 2017, closing a stake of 123,713 shares — an estimated $9.43M sold.

Highbridge Capital Management first reported a position in CRL in Q3 2013 and held it in 5 quarters. The position peaked at $10.7M in Q3 2015. 300 funds tracked by Wall St. Rank hold CRL as of Q1 2017.

Highbridge Capital Management reported no remaining Charles River Laboratories position as of Q1 2017 after selling out during the quarter.
Highbridge Capital Management sold 123,713 Charles River Laboratories shares in Q1 2017, an estimated $9.43M.
Highbridge Capital Management first reported a position in Charles River Laboratories in Q3 2013 and held it in 5 quarters.
Highbridge Capital Management's Charles River Laboratories position peaked at $10.7M in Q3 2015.
300 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2017.

Based on Highbridge Capital Management's 13F filing for Q1 2017, filed 15 May 2017.